Alexion is focused on transforming the lives of people living with rare diseases through the development and delivery of valued innovative medicines.

Soliris® (Eculizumab)
The world's first approved complement inhibitor for the treatment of patients with:
- NMOSD (Neuromyelitis Optica Spectrum Disorder)
- PNH (Paroxysmal Nocturnal Hemoglobinuria)
- aHUS (Atypical Hemolytic Uremic Syndrome)
- AchR+ gMG (Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis)

Ultomiris® (Ravulizumab-CWV2)
The first and only long-acting C5 inhibitor for the treatment of:
- Adults and pediatric patients one month of age and older with aHUS (Atypical Hemolytic Uremic Syndrome) to inhibit complement-mediated thrombotic microangiopathy (TMA)
- PNH (Paroxysmal Nocturnal Hemoglobinuria)

Strensiq® (Asfotase Alfa)
For the treatment of patients with:
- HPP (Hypophosphatasia)

Kanuma® (Sebelipase Alfa)
For the treatment of patients with:
- LAL-D (Lysosomal Acid Lipase Deficiency)

Koselugo® (Selumetinib)
The first and only FDA-approved treatment for children 2 years of age and older with:
- NF1 (Neurofibromatosis Type 1)
- PNX (Plexiform Neurofibromas)
Our innovation begins with understanding people living with rare diseases, which fuels all of our efforts, beginning with our own medicine discovery efforts, as well as collaboration with external partners.

**OUR VALUES**

- We Follow the Science
- We Put Patients First
- We Play to Win
- We Do the Right Thing
- We are Entrepreneurial

**ALEXION’S PHASE 3 PROGRAMS INCLUDE:**

- **ULTOMIRIS®** *(ravulizumab-cwvz)*, a long-acting C5 inhibitor, for:
  - Subcutaneous QW for aHUS & PNH
  - Neuromyelitis Optica Spectrum Disorder (NMOSD)
  - Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA)

- **KOSELUGO®** *(selumetinib)*, a kinase inhibitor, for Neurofibromatosis Type 1 (NFI), Plexiform Neurofibromas (PN) in adults.

- **ALXN1840**, an investigational, oral, targeted de-coppering therapy, for Wilson disease.

- **Anselamibab (CAEL-101)**, an investigational first-in-class amyloid fibril targeted therapy, for AL Amyloidosis.

- **Danicopan (ALXN2040)**, an investigational, oral, factor D inhibitor, for PNH with extravascular hemolysis (EVH).

- **Acoramidis**, an investigational, oral, small molecule for Transthyretin Amyloid Cardiomyopathy (ATTR-CM). Alexion holds an exclusive license to develop and commercialize acoramidis in Japan.

- **Gefurulimab**, an investigational, anti-C5 albumin-binding humanized bispecific VvH antibody optimized for subcutaneous delivery.

**ALEXION HAS ADDITIONAL R&D PROGRAMS IN COLLABORATION WITH:**

- DICERNA
- MERCK
- NEURIMMUNE
- ZEALAND PHARMA

At Alexion, our passion drives us to continuously innovate and create meaningful value in all we do. In doing so, we change lives for the better – ours, people living with rare diseases and devastating conditions, and the communities we serve. Every day.